非药理学的方法来管理心力衰竭与保存的喷射分数的管理
Feiyang Tang1,2, Haofu Han1,2, Sheng Fu3
1Department of Cardiovascular Medicine, Second Xiangya Hospital (F.T., H.H., Q.L., S.Z., Y.X.), Central South University, Changsha, China.
Circulation. Heart failure
|June 18, 2024
概括
非药物治疗为心力衰竭提供了新的希望,其中保留了喷射分数 (HFpEF). 新兴的疗法,如迷走神经刺激和脏缩,有望改善HFpEF患者的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 医疗技术 医疗技术 医学技术
背景情况:
- 保持喷射分数 (HFpEF) 的心力衰竭的特征是腹功能障碍和心肌顺应性降低.
- 对于HFpEF存在有限的基于证据的药理疗法,这引发了对非药理替代品的兴趣.
研究的目的:
- 审查HFpEF的病理生理学.
- 介绍HFpEF非药物管理策略的最新进展.
主要方法:
- 广泛的文献审查,以识别和综合新兴的非药物治疗选择.
- 评估这些策略在改善患者治疗结果方面的潜力.
主要成果:
- 包括迷走神经刺激,肺动脉缩,脏缩,心房转移和心周切除在内的非药理学策略显示出有前途.
- 治疗诸如高血压和糖尿病之类的并发症可能会增强治疗效益.
- 既定的运动疗法仍然至关重要.
结论:
- 非药理干预措施具有改善HFpEF患者护理的巨大潜力.
- 需要进一步的研究和临床应用来推进HFpEF的向疗法.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
420
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
420
Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Heart Failure Drugs: Inotropic Agents
564
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
564
Pathophysiology of Cardiac Performance
632
Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
632


